Skip to content
Peptigraph home

Tesamorelin for Diabetes: What the Evidence Shows

What human and animal studies show about Tesamorelin for diabetes, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRH analogUpdated
Strongest evidence
None graded
no study with an outcome for diabetes (PubMed search, 11 Oct 2026)
Human studies
None found
with an outcome for diabetes, in our evidence file (PubMed search, 11 Oct 2026)
Animal studies
None found
with an outcome for diabetes, in our evidence file (PubMed search, 11 Oct 2026)

Evidence for diabetes

None of the study abstracts we summarised for Tesamorelin reported an outcome for diabetes (PubMed search, 11 Oct 2026). Claims that it helps with diabetes are unproven.

How strong is it?

Strongest evidence:No graded study for diabetes (PubMed search, 11 Oct 2026)

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Diabetes and glucose

MedlinePlus says that in diabetes the body doesn't make enough insulin or doesn't use insulin well.[4]

What glucose results the tesamorelin trials reported

In the first phase 3 HIV trial, glycemic measures did not differ significantly between tesamorelin and placebo.[5]

The second phase 3 trial likewise saw no change in glucose parameters in its efficacy phase.[6]

Over 52 weeks of treatment, glucose changes were not clinically significant and matched those at 26 weeks.[7]

In people with fatty liver and HIV, fasting glucose and HbA1c did not differ between groups at 12 months.[8]

In obese adults with relatively low GH, tesamorelin reduced visceral fat and improved triglycerides without worsening glucose.[9]

Label wording and responders

The Egrifta WR label warns that treatment can cause glucose intolerance, with HbA1c of 6.5% or more in 5% of tesamorelin patients versus 1% on placebo by week 26.[10]

The label tells patients that glucose will be monitored and that anti-diabetic medicines may need adjusting if they already have diabetes.[10]

In responders with at least 8% visceral fat reduction, glucose homeostasis was preserved over 52 weeks.[11]

Other peptides people research for diabetes

All peptides for diabetes, compared

Common questions

Does Tesamorelin help with diabetes?

None of the studies we summarised for Tesamorelin (PubMed search, 11 Oct 2026) measured an outcome for diabetes. Treat claims that it helps with diabetes as unproven.

Is tesamorelin approved for diabetes?

No. It is indicated for excess abdominal fat in HIV-infected adults with lipodystrophy.[10]

What is the best peptide for diabetes?

There is no single answer. Our diabetes overview compares each candidate by evidence grade and legal status rather than by popularity.

Does tesamorelin help insulin resistance?

The first phase 3 HIV trial reported no significant differences in glycemic measures. No trial result on insulin resistance itself is cited here.[5]

Can tesamorelin raise blood sugar?

The label warns it can cause glucose intolerance, with HbA1c of 6.5% or more in 5% versus 1% by week 26.[10]

More on Tesamorelin

Sources

  1. 1PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) (104 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2PubMed search: (tesamorelin[tiab] OR TH9507[tiab]) AND (pharmacokinetic*[tiab] OR half-life[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (36 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  4. 4medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
  5. 5Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  6. 6Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Journal of acquired immune deficiency syndromes (1999) · 2010PMID 20101189Accessed 2 Oct 2026
  7. 7Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
  8. 8Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  9. 9Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
  10. 10EGRIFTA WR prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  11. 11Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012PMID 22495074Accessed 2 Oct 2026

Found an error? Report a correction.